News & Events

A poll has been sent to Industry Members' emails to schedule the first Industry Liaison Committee Meeting in the coming weeks.

We shall be updating Participants of the iPSC Quality Assessment Round on the manuscript shortly. A professional statistician re-analysed the amalgamated dataset to fortify the paper.

GAiT is also planning its first Industry Liaisons committee meeting. Internal discussions with GAiT Director / CCRM President & CEO Michael May, to discuss schedule, materials, and format, will take place this week. GAiT will then reach out to Industry members directly.

We appreciate Participants' patience - internal reviewers of the paper were dealing with the COVID-19 response, delaying matters. As agreed, we will allow a final review before submission.

GAiT has been reorganizing for the next stage in its growth and development. More ambitious goals necessitated internal reviews, strategic decisions, and system restructuring. Thankfully our operations are now again normalized and we shall now be more communicative with members.

Happy International Women's Day. Half of GAiT's Directors are women: Jacqueline Barry (CGTCatapult), Susan Solomon (NYSCF) and Annelise Bennaceur Griscelli (INSERM).

To avail of an extra three months of GAiT industry membership at no extra cost, remember to pay your annual industry subscription this week.

Pluripotent Stem Cell Manufacturing Expert Panels - developing action plans to deal with common challenges http://gait.global/expert-panels-2019-agenda/ We look forward to the follow up meeting later this year.

Industry membership subscriptions are now due. Pay before 10th March and extend your company's membership an extra three months at no extra cost.

Before COVID-19, we built a network of QC experts, transplantation experts, developers, manufacturers, registry managers, regulatory affairs experts & other stakeholders to map out an efficient roadmap for iPSC therapeutics. We now work online but the work continues.